Hikma Pharmaceuticals launches Adriamycin for injection
Hikma Pharmaceuticals has launched Adriamycin (DOXOrubicin HCl) for injection in 10 mg and 50 mg dosage strengths.
The product is an anthracycline topoisomerase II inhibitor indicated as a component of multi-agent adjuvant chemotherapy for the treatment of women with axillary lymph node involvement following resection of primary breast cancer.
Additionally, Doxorubicin is indicated for the treatment of such other cancer as acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma and metastatic bronchogenic carcinoma.
The product had a market value of approximately $13 million in the 12 months ending July 2018, according to IQVIA.
The product is an anthracycline topoisomerase II inhibitor indicated as a component of multi-agent adjuvant chemotherapy for the treatment of women with axillary lymph node involvement following resection of primary breast cancer.
Additionally, Doxorubicin is indicated for the treatment of such other cancer as acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma and metastatic bronchogenic carcinoma.
The product had a market value of approximately $13 million in the 12 months ending July 2018, according to IQVIA.